

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 09 day of August 2006.

By

(Signature of person mailing)

Andrea E. Dorigo

Reg. No. 47,532

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Justin S Bryans et al

Examiner: **Unknown**

APPLICATION NO.: PCT/IB05/000079

Group Art Unit: **Unknown**

FILING DATE: 01/11/05

TITLE: COMPOUNDS USEFUL IN THERAPY

Mail Stop: Petition

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

PETITION FOR REVIVAL OF UNINTENTIONALLY ABANDONED APPLICATION **UNDER 37 C.F.R. §1.137(b)**

Applicants respectfully petition for revival of the above-captioned international application. Pursuant to 35 USC 363, "[a]n international application designating the United States shall have the effect, from its international filing date under article 11 of the treaty, of a national application for patent regularly filed in the Patent and Trademark Office except as otherwise provided in section 102(e) of this title." The above-captioned international application designated the United States, was published in English as WO 2005/079808, and was filed on January 11, 2005. Accordingly, per 35 USC 363, the above-captioned application has the effect of a "national application for patent regularly filed." However, Applicants, had inadvertently neglected to either enter national phase in the U.S. or to file a continuation application in a timely fashion before the 30-month deadline expiration calculated from the priority date of January 22, 2004. The date of abandonment is the day after the expiration date of the 30-month period, that is, July 23 2006.

Applicants hereby petition for revival of this application. A submission under 35 USC 371 to enter National Phase of this application is filed concurrently herewith.

Pursuant to 37 CFR 1.137(b), applicants also state the following:

08/16/2006 EXAMFEBH 00000071 161445 10500076

34 FC:1453 1500.00 34


a) the entire delay in either entering national phase in the U.S. or filing a continuation application from the due date of July 23 2006 until the filing of a grantable petition under 37 CFR § 1.137(b) was unintentional;

b) since this utility/plant application was filed on January 11, 2005, no terminal disclaimer is required; and

c) the petition fee is the fee for other than a small entity under 37 CFR § 1.17(m). The Commissioner is hereby authorized to charge this fee to Deposit Account No. 16-1445.

The Commissioner is also hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Date: August 09, 2006



Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-1898